Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Share:
Related MRK
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
The Vetr community has downgraded $MRK to 2.5-Stars (Vetr)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2017GuggenheimUpgradesNeutralBuy
Jan 2017Morgan StanleyUpgradesEqual-WeightOverweight
Dec 2016JefferiesDowngradesHoldUnderperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!